FDA Greenlights First 6‑Month HIV Prevention Injection
Clinical trials show lenacapavir injections every six months offer nearly complete protection against HIV. The U.S. FDA has officially approved Gilead’s long‑acting capsid inhibitor for pre‑exposure prophylaxis, branded Yeztugo. This milestone marks the first preventive use of lenacapavir, previously approved for treatment of drug-resistant HIV. The shift from daily pills to biannual injections could significantly improve adherence, especially in populations struggling with routine medication. However, concerns remain over its steep price—approximately $28,218 annually in the U.S.—raising questions about equity of access. Pending broader health system negotiations, insurance coverage, manufacturing scale-up, and pricing policy will be critical to ensuring this advance doesn’t widen existing disparities. (Wired)
Industry Decries Sudden Ouster of FDA Cell & Gene Therapy Leader
The FDA abruptly placed Nicole Verdun, director of its Cell & Gene Therapy Office, and deputy Rachael Anatol on administrative leave, escorting them from the premises. Their removal intensified concerns about the agency’s leadership stability, especially following 2023’s exit of Peter Marks. Verdun was seen as a steadying, science‑centric executive guiding approvals of advanced therapies. The Alliance for Regenerative Medicine criticized the move as unpredictable, worrying it could hinder regulatory clarity for developers of cell and gene treatments. No reasons were provided. Industry insiders stress that continuity and transparent communication are essential to maintain momentum in biotech innovation and patient access. (Fierce Biotech)
Comprehensive RCT Spreadsheet Challenges Vaccine Misinformation
A volunteer-led project compiled a master spreadsheet cataloging every randomized controlled trial (RCT) conducted for licensed non-flu vaccines. Initiated to challenge misinformation—especially claims by prominent skeptics that childhood vaccines lack placebo-controlled trials—the list details trials’ designs, outcomes, and demographics. It aims to increase transparency and accessibility of vaccine safety and efficacy data. Launched via social media, the tool supports evidence-based discussions and acts as a resource for researchers, clinicians, and the public. By allowing users to verify thousands of trial entries, the initiative hopes to dispel myths and improve trust in established vaccines without referencing any other COVID-19–specific research. (CIDRAP)
New mRNA Technique Programs Body to Cargo Its Own CAR‑T Cells
Scientists report a breakthrough method using mRNA delivered via lipid nanoparticles to reprogram T cells inside the patient’s body into CAR‑T cells. This approach bypasses ex vivo engineering, potentially simplifying treatment for cancer and autoimmune diseases. Animal studies indicate targeted lipid nanoparticles can deliver genetic instructions to T cells, prompting them to express chimeric antigen receptors that identify and eliminate disease-causing cells. This innovation could significantly reduce costs, increase accessibility, and enhance the speed of CAR-T therapy deployment. However, clinical trials and safety evaluations in humans are still needed to confirm effectiveness and potential side effects. (Science)
Hacktivists Linked to Israel Hit Iran’s Financial Infrastructure
A hacker group known as Predatory Sparrow—allegedly connected to Israel—has claimed responsibility for destructive cyberattacks on Iran’s financial system. The group disrupted Septah Bank’s operations and destroyed over $90 million in cryptocurrency on Nobitex exchange, transferring funds to irretrievable addresses bearing anti‑IRGC messages. These actions serve both political and symbolic goals, targeting institutions tied to Iran’s military and regime. Experts say the sophistication and destructive intent mark a sharp escalation in cyberwarfare, raising the stakes of digital conflict between nations. The incidents reflect an increasingly volatile cyberspace battleground between Iran and its adversaries. (Ars Technica)
Aflac Reports U.S. Network Breach, Offers Credit Monitoring
Aflac has detected suspicious activity on its U.S. network—identified June 12—and moved swiftly to halt the intrusion. The breach may have compromised sensitive data, including Social Security numbers, health data, and claims files belonging to policyholders, employees, and agents. The insurer has retained cybersecurity experts and is offering two years of free credit monitoring, ID theft protection, and medical shield services. As investigations continue, the full scope of affected individuals remains unclear. The incident is part of a wider trend of cyberattacks targeting insurance and health firms. Aflac’s shares dropped 1.3% following the announcement. (CNN)
Phone Users Disable Alerts Due to “Alert Fatigue”
A global study reveals “alert fatigue” as users become overwhelmed by news notifications—some receiving up to 50 alerts daily. Around 43% of those surveyed have disabled alerts, citing excessive volume and irrelevance. While usage grew since 2014, particularly in the U.S. and U.K., publishers risk losing audiences if messages aren’t judicious. Some outlets already limit alerts (e.g., four per day), while others bombard users. Experts warn that aggressive alerting might prompt users to uninstall apps or force platforms like Apple and Google to enforce stricter controls. News providers are urged to balance urgency with restraint to maintain engagement. (The Guardian)
Animal Regeneration Research May Spur Human Healing
Studies on organisms such as worms, zebrafish, and lizards reveal powerful regenerative abilities—like regrowing limbs and organs. Researchers are investigating the underlying molecular pathways (e.g., signaling mechanisms and stem-cell activation) to translate into human therapies. The goal is to enhance recovery from injuries by reactivating dormant repair systems. While humans possess limited regenerative capability, understanding these model species could unlock treatments for degenerative diseases, spinal cord injuries, or heart damage, potentially transforming medicine from managing conditions to restoring tissue. (Nature)
Early Homo sapiens Thrived in Diverse African Environments Long Before Migration
Research shows Homo sapiens adapted to environments ranging from savannas and forests to rainforests and deserts between 120,000 and 14,000 years ago. Starting around 70,000 years ago, humans expanded beyond familiar niches into more extreme habitats across Africa. Climate modeling, coupled with archaeological data, suggests this ecological flexibility prepared populations for global migration around 50,000 years ago. The study debunks the myth that migration was driven by breakthroughs; instead, survival hinged on adaptability. However, it doesn’t fully explain why Homo sapiens became the sole human species in history. (AP)
Naomi Oreskes: Science Under Threat When It Challenges Power
Harvard professor Naomi Oreskes warns that scientific knowledge becomes vulnerable when it threatens authority—historically as seen under Stalin-era Lysenkoism and today amid political attacks by figures like Donald Trump. Budget cuts and ideological interference are undermining public trust in areas like climate change and vaccines. Oreskes argues the solution lies in empowering citizens to critically assess evidence and for science to improve its communication strategies. With disinformation funded by corporate and political interests, scientific integrity depends on both better dialogue and civic engagement with reliable sources. (El Pais)
Thanks for reading. Let’s be careful out there.
WORDS: The Biology Guy.
Leave a Reply